AU2008205376B2 - High affinity antibodies that neutralize Staphylococcus enterotoxin B - Google Patents

High affinity antibodies that neutralize Staphylococcus enterotoxin B Download PDF

Info

Publication number
AU2008205376B2
AU2008205376B2 AU2008205376A AU2008205376A AU2008205376B2 AU 2008205376 B2 AU2008205376 B2 AU 2008205376B2 AU 2008205376 A AU2008205376 A AU 2008205376A AU 2008205376 A AU2008205376 A AU 2008205376A AU 2008205376 B2 AU2008205376 B2 AU 2008205376B2
Authority
AU
Australia
Prior art keywords
seq
antibody
heavy chain
light chain
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008205376A
Other languages
English (en)
Other versions
AU2008205376A1 (en
Inventor
Marc Berger
Luigi Grasso
Nicholas C. Nicolaides
Tao Sai
Philip M. Sass
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Inc
Original Assignee
Eisai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Inc filed Critical Eisai Inc
Publication of AU2008205376A1 publication Critical patent/AU2008205376A1/en
Application granted granted Critical
Publication of AU2008205376B2 publication Critical patent/AU2008205376B2/en
Priority to AU2012241059A priority Critical patent/AU2012241059B2/en
Assigned to EISAI, INC. reassignment EISAI, INC. Request for Assignment Assignors: MORPHOTEK, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2008205376A 2007-01-03 2008-01-03 High affinity antibodies that neutralize Staphylococcus enterotoxin B Active AU2008205376B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012241059A AU2012241059B2 (en) 2007-01-03 2012-10-11 High affinity antibodies that neutralize Staphylococcus enterotoxin B

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US88327107P 2007-01-03 2007-01-03
US60/883,271 2007-01-03
US88840507P 2007-02-06 2007-02-06
US60/888,405 2007-02-06
PCT/US2008/000104 WO2008085878A2 (en) 2007-01-03 2008-01-03 High affinity antibodies that neutralize staphylcoccus enterotoxin b

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2012241059A Division AU2012241059B2 (en) 2007-01-03 2012-10-11 High affinity antibodies that neutralize Staphylococcus enterotoxin B

Publications (2)

Publication Number Publication Date
AU2008205376A1 AU2008205376A1 (en) 2008-07-17
AU2008205376B2 true AU2008205376B2 (en) 2012-07-12

Family

ID=39529113

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008205376A Active AU2008205376B2 (en) 2007-01-03 2008-01-03 High affinity antibodies that neutralize Staphylococcus enterotoxin B

Country Status (9)

Country Link
US (6) US8236932B2 (https=)
EP (2) EP2109622B1 (https=)
JP (3) JP5412293B2 (https=)
AU (1) AU2008205376B2 (https=)
CA (2) CA2924155C (https=)
DK (1) DK2109622T3 (https=)
ES (1) ES2619943T3 (https=)
PL (1) PL2109622T3 (https=)
WO (1) WO2008085878A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236932B2 (en) 2007-01-03 2012-08-07 Morphotek, Inc. High affinity antibodies that neutralize Staphylococcus enterotoxin B
US20110166076A1 (en) * 2008-09-10 2011-07-07 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
WO2013089877A2 (en) * 2011-09-27 2013-06-20 Albert Einstein College Of Medicine Of Yeshiva University Adjuvant therapy for staphylococcal infection with enterotoxin specific mabs
CN103946236B (zh) * 2011-11-23 2018-02-16 弗·哈夫曼-拉罗切有限公司 表达cd40l的哺乳动物细胞及其用途
US20160039914A1 (en) * 2013-03-14 2016-02-11 Albert Einstein College Of Medicine Of Yeshiva University Humanized antibodies specific for staphylococcal enterotoxin b
EP3532497B1 (en) * 2016-10-26 2024-07-24 The Board of Trustees of the Leland Stanford Junior University Modified immunoglobulin hinge regions to reduce hemagglutination
US20230192896A1 (en) * 2016-11-23 2023-06-22 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
KR102124258B1 (ko) * 2018-10-19 2020-06-26 대한민국(관리부서 질병관리본부장) 신속 면역크로마토그래피법을 이용한 황색 포도알균 장독소 b 진단·탐지 키트 및 이를 위한 특이항체와 항체생산세포주
EP4051711A4 (en) * 2019-11-01 2024-02-21 Magenta Therapeutics, Inc. ANTI-CD45 ANTIBODIES AND THEIR CONJUGATES
KR102274759B1 (ko) * 2020-01-16 2021-07-09 대한민국(질병관리청장) 황색포도알균 장독소 b에 특이적인 항체 및 이의 용도
CN119101153B (zh) * 2024-04-30 2025-07-08 中国人民解放军军事科学院军事医学研究院 一种葡萄球菌肠毒素b纳米抗体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006213321A2 (en) * 2005-02-08 2006-08-17 Km Biologics Co., Ltd. Method for improving antibody

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2574089A (en) 1948-06-08 1951-11-06 Cochran Jacqueline Luggage case having a removable lining
US4854432A (en) 1988-07-06 1989-08-08 American Tourister, Inc. Suitcase having removable divider with clothing pockets
US6713610B1 (en) * 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
CA2194450A1 (en) 1994-07-06 1996-01-18 Truckin' Movers Corporation Convertible carrying case and work platform
US6036697A (en) 1998-07-09 2000-03-14 Scimed Life Systems, Inc. Balloon catheter with balloon inflation at distal end of balloon
CA2345023A1 (en) 1998-10-07 2000-04-13 The Rockefeller University Peptides useful for reducing symptoms of toxic shock syndrome and septic shock
EP1532175B1 (en) 2002-03-22 2012-10-17 Aprogen, Inc. Humanized antibody and process for preparing the same
US20050240009A1 (en) 2002-08-21 2005-10-27 Carr Francis J T-cell epitopes in staphylococcal enterotoxin b
WO2005023853A1 (ja) * 2003-09-05 2005-03-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute プロテアーゼ耐性ｓｅｂ改変体およびそれを含むワクチン
WO2007141274A2 (en) * 2006-06-06 2007-12-13 Crucell Holland B.V. Human binding molecules having killing activity against staphylococci and uses thereof
US8236932B2 (en) * 2007-01-03 2012-08-07 Morphotek, Inc. High affinity antibodies that neutralize Staphylococcus enterotoxin B

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006213321A2 (en) * 2005-02-08 2006-08-17 Km Biologics Co., Ltd. Method for improving antibody

Also Published As

Publication number Publication date
CA2924155A1 (en) 2008-07-17
EP3138852A1 (en) 2017-03-08
PL2109622T3 (pl) 2017-06-30
WO2008085878A2 (en) 2008-07-17
AU2008205376A1 (en) 2008-07-17
CA2674382C (en) 2016-05-31
US20170121396A1 (en) 2017-05-04
JP5412293B2 (ja) 2014-02-12
EP2109622A2 (en) 2009-10-21
US9868780B2 (en) 2018-01-16
DK2109622T3 (en) 2017-02-13
US8236932B2 (en) 2012-08-07
US8895704B2 (en) 2014-11-25
US20150050276A1 (en) 2015-02-19
JP2013216673A (ja) 2013-10-24
US20180094048A1 (en) 2018-04-05
US8889846B2 (en) 2014-11-18
US20130183314A1 (en) 2013-07-18
WO2008085878A3 (en) 2009-02-26
CA2674382A1 (en) 2008-07-17
JP5881646B2 (ja) 2016-03-09
JP2016146824A (ja) 2016-08-18
US20120171223A1 (en) 2012-07-05
EP2109622B1 (en) 2016-11-09
US9359428B2 (en) 2016-06-07
JP6195946B2 (ja) 2017-09-13
US10364284B2 (en) 2019-07-30
JP2010514459A (ja) 2010-05-06
CA2924155C (en) 2020-02-11
ES2619943T3 (es) 2017-06-27
US20140072553A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
US10364284B2 (en) High affinity antibodies that neutralize Staphylococcus enterotoxin B
US20230331824A1 (en) Single-domain antibodies that bind sars-cov-2
US20240182548A1 (en) Sars-cov-2 antibodies and methods of selecting and using the same
KR20110025859A (ko) 항-ｇｄ２ 항체 및 이와 관련된 방법 및 용도
EP2220117A2 (en) Antibodies to the pcrv antigen of pseudomonas aeruginosa
HK1216428A1 (zh) 血小板衍生生长因子b之特异性抗体及其组合物和用途
TR201808486T4 (tr) Bradikinin B1 reseptör ligandlarına karşı antikorlar.
WO2022150740A1 (en) Cross-reactive antibodies recognizing the coronavirus spike s2 domain
CN112552411B (zh) 新型抗pd-l1/抗lag-3双特异性抗体及其用途
AU2012241059B2 (en) High affinity antibodies that neutralize Staphylococcus enterotoxin B
US20240294611A1 (en) Cross-reactive antibodies recognizing the coronavirus spike s2 domain
WO2026072786A1 (en) Clostridium difficile binary toxin neutralizing antibodies
WO2024211789A1 (en) Cross-flavivirus binding domains and uses thereof
WO2024150074A2 (en) Coronavirus antibodies and therapeutic uses thereof
Wang The adenylate cyclase toxin as a target for antibody therapeutics and vaccination against whooping cough
HK40044140B (en) Novel anti-pd-1 antibodies
HK40044140A (en) Novel anti-pd-1 antibodies

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ HIGH AFFINITY ANTIBODIES THAT NEUTRALIZE STAPHYLOCOCCUS ENTEROTOXIN B

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: EISAI, INC.

Free format text: FORMER OWNER(S): MORPHOTEK, INC.